ARVN opened at $6.37 on Monday. The firm has a market cap of $438.08 million, a PE ratio of -2.30 and a beta of 2.30. The stock has a 50-day moving average price of $13.91 and a 200-day moving ...

So should Arvinas (NASDAQ:ARVN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

Arvinas, Inc. (ARVN) has been on a downward spiral lately with significant selling pressure. After declining 25.4% over the past four weeks, the stock looks well positioned for a trend reversal as ...

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $32.00. The company’s shares ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports.

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $24.00. The company’s shares ...

Price Action: ARVN stock is down 4.93% at $6.56 at the last check on Friday.

Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the ...

Arvinas, Inc. (NASDAQ:ARVN) develops treatments that break down disease-causing proteins using its PROTAC (Proteolysis Targeting Chimera) technology. The company’s main drugs target prostate ...

The loss by the Army of the Republic of Vietnam (ARVN) underscored the total dependence of the Saigon government on direct American military intervention, which had been withdrawn as a result of ...